WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCAB

Based on 2 analysts offering 12 month price targets for Bioatla Inc.
Min Forecast
$5.00+112.77%
Avg Forecast
$6.00+155.32%
Max Forecast
$7.00+197.87%

Should I buy or sell BCAB stock?

Based on 2 analysts offering ratings for Bioatla Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCAB stock forecasts and price targets.

BCAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-16
lockedlocked$00.00+00.00%2024-05-15

1 of 1

Forecast return on equity

Is BCAB forecast to generate an efficient return?
Company
-208.01%
Industry
-762.05%
Market
49.3%
BCAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCAB forecast to generate an efficient return on assets?
Company
-95.07%
Industry
26.89%
BCAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCAB earnings per share forecast

What is BCAB's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$1.52
Avg 2 year Forecast
-$1.74
Avg 3 year Forecast
-$1.63

BCAB revenue forecast

What is BCAB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$19.7M
Avg 2 year Forecast
$42.2M
Avg 3 year Forecast
$118.2M

BCAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAB$2.35$6.00+155.32%Buy
IVVD$0.96$12.00+1,148.70%Strong Buy
NVCT$6.16$21.00+240.91%Buy
VSTM$2.77$12.50+351.26%Strong Buy
GUTS$2.31N/AN/A
View Top Biotech Stocks

Bioatla Stock Forecast FAQ

Is Bioatla Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BCAB) stock is to Buy BCAB stock.

Out of 2 analysts, 0 (0%) are recommending BCAB as a Strong Buy, 2 (100%) are recommending BCAB as a Buy, 0 (0%) are recommending BCAB as a Hold, 0 (0%) are recommending BCAB as a Sell, and 0 (0%) are recommending BCAB as a Strong Sell.

If you're new to stock investing, here's how to buy Bioatla stock.

What is BCAB's earnings growth forecast for 2024-2026?

(NASDAQ: BCAB) Bioatla's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.

Bioatla's earnings in 2024 is -$104,556,000.On average, 1 Wall Street analyst forecast BCAB's earnings for 2024 to be -$73,470,320, with the lowest BCAB earnings forecast at -$73,470,320, and the highest BCAB earnings forecast at -$73,470,320. On average, 1 Wall Street analyst forecast BCAB's earnings for 2025 to be -$84,104,182, with the lowest BCAB earnings forecast at -$84,104,182, and the highest BCAB earnings forecast at -$84,104,182.

In 2026, BCAB is forecast to generate -$78,787,251 in earnings, with the lowest earnings forecast at -$78,787,251 and the highest earnings forecast at -$78,787,251.

What is BCAB's revenue growth forecast for 2026-2028?

(NASDAQ: BCAB) Bioatla's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.61%.

Bioatla's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BCAB's revenue for 2026 to be $952,214,019, with the lowest BCAB revenue forecast at $952,214,019, and the highest BCAB revenue forecast at $952,214,019. On average, 2 Wall Street analysts forecast BCAB's revenue for 2027 to be $2,037,834,672, with the lowest BCAB revenue forecast at $900,011,423, and the highest BCAB revenue forecast at $3,175,657,921.

In 2028, BCAB is forecast to generate $5,712,607,413 in revenue, with the lowest revenue forecast at $4,513,204,435 and the highest revenue forecast at $6,912,010,391.

What is BCAB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BCAB) forecast ROA is -95.07%, which is lower than the forecast US Biotechnology industry average of 26.89%.

What is BCAB's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BCAB price target, the average BCAB price target is $6.00, with the highest BCAB stock price forecast at $7.00 and the lowest BCAB stock price forecast at $5.00.

On average, Wall Street analysts predict that Bioatla's share price could reach $6.00 by Sep 16, 2025. The average Bioatla stock price prediction forecasts a potential upside of 155.32% from the current BCAB share price of $2.35.

What is BCAB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: BCAB) Bioatla's current Earnings Per Share (EPS) is -$2.18. On average, analysts forecast that BCAB's EPS will be -$1.52 for 2024, with the lowest EPS forecast at -$1.52, and the highest EPS forecast at -$1.52. On average, analysts forecast that BCAB's EPS will be -$1.74 for 2025, with the lowest EPS forecast at -$1.74, and the highest EPS forecast at -$1.74. In 2026, BCAB's EPS is forecast to hit -$1.63 (min: -$1.63, max: -$1.63).

What is BCAB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BCAB) forecast ROE is -208.01%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.